Apoquel (oclacitinib maleate) works fast and, for many dogs with atopic dermatitis, it works well. But because it modulates the JAK-STAT immune signaling pathway, the safety conversation is different from antihistamines or essential fatty acids. Owners who know what to watch for — and veterinarians who set a monitoring plan before the first tablet — catch problems earlier and avoid gaps that can be hard to undo.

This article focuses specifically on side effects, monitoring, and the owner-veterinarian conversation around long-term oclacitinib use. For how Apoquel works, when it is prescribed, and how it compares to Cytopoint, Zenrelia, or Atopica, see the general Apoquel overview and the Apoquel vs Cytopoint comparison.

What the label actually says about risk

The FDA-approved label for oclacitinib (NADA 141-345) includes the following warnings:

• Not for dogs under 12 months of age. In a margin-of-safety study, 6-month-old dogs given 3× and 5× the label dose developed demodicosis and bacterial pneumonia at rates the FDA considered unacceptable.
• May increase susceptibility to infection, including demodicosis, and may exacerbate neoplastic (cancerous) conditions.
• Should not be used in dogs with serious infections.
• Not for use in breeding dogs, or pregnant or lactating bitches.
• Has not been evaluated in combination with glucocorticoids, cyclosporine, or other systemic immunosuppressive agents for long-term concurrent use.

In 2021, the FDA required Zoetis to update the label to state that Apoquel "modulates the immune system" and that new neoplastic conditions have been observed in clinical studies and reported in the post-approval period. An FDA untitled letter in 2018 also took Zoetis to task for promotional materials that described Apoquel as having "minimal side effects" — the agency found that characterization false and misleading given the labeled warnings.

The most common side effects in clinical trials

Across the pre-marketing field studies (the data that underpin the prescribing information), the most frequently reported adverse events were:

These were generally mild and often transient. In the 30-day masked phase of the pivotal field trial, GI signs led to withdrawal in a small number of dogs, but most continued dosing without dose adjustment.

The UK Veterinary Medicines Directorate (VMD), which maintains adverse event data from the same drug's European authorization, classifies reported side effects by frequency:

This frequency data is important context: the side effects most owners worry about (cancer, seizures) are in the "very rare" category, while the side effects most likely to occur (skin infections, GI upset, new benign lumps) are common and usually manageable.

The monitoring conversation most owners never get

The European label — which is the same drug reviewed by the same manufacturer — explicitly recommends "periodic monitoring with complete blood counts and serum biochemistry" for dogs on long-term treatment. The US label is less prescriptive about frequency, but the pharmacovigilance data support the same principle.

A practical monitoring protocol, consistent with what academic dermatology services and specialty hospitals recommend, looks like this:

What "CBC, chemistry" actually means in plain language

If your veterinarian recommends blood work, they are checking:

• White blood cell counts (neutrophils, lymphocytes). Oclacitinib's mechanism — inhibiting JAK1 — can reduce the production of white blood cells in the bone marrow. A falling trend, even if still "normal" on paper, is the early signal.
• Globulins. These immune proteins can decrease on oclacitinib. A meaningful drop may indicate immune suppression beyond what the label intended.
• Cholesterol and lipase. Both can increase. In isolation this is usually not dangerous, but it matters if the dog has concurrent pancreatitis risk or is on other medications that affect lipase.
• Liver enzymes. The drug is metabolized hepatically. Baseline liver values help your veterinarian interpret future changes.

Infection risk: what actually happens

The label warns about increased susceptibility to infection. In practice, the infections most commonly seen are:

• Skin infections (pyoderma) and ear infections (otitis) — not surprising in dogs already prone to allergic skin disease.
• Urinary tract infections — some long-term studies noted a slightly elevated rate.
• Demodicosis — reactivation of dormant Demodex mites. This is more likely in dogs with a prior history and is one reason the label contraindicates use in dogs with a history of recurrent demodicosis.
• Pneumonia — rare, but it was a signal in the margin-of-safety study at supra-label doses and in the post-approval pharmacovigilance database.

If your dog develops repeated infections while on Apoquel, the conversation with your veterinarian should include whether the drug is contributing, whether the dose can be reduced, or whether an alternative approach (such as Cytopoint, which is not immunosuppressive) would be more appropriate.

Neoplasia: the question every owner asks

The label states that oclacitinib "may exacerbate neoplastic conditions." This is the warning that generates the most owner anxiety and the most online discussion. Here is what the evidence actually shows:

• In the original clinical trials, several dogs developed malignant tumors during the study period. However, these were generally older dogs (atopic dermatitis predominantly affects middle-aged and older dogs), and the incidence was not statistically different from what would be expected in an aging dog population with a high cancer background rate.
• A 2025 comprehensive pharmacovigilance review (Nederveld et al., Journal of Veterinary Pharmacology and Therapeutics) — authored by Zoetis employees but peer-reviewed — found that an age- and breed-matched retrospective cohort study showed no significant difference in neoplasia incidence between dogs treated with oclacitinib and dogs treated with other systemic allergy therapies.
• A veterinary dermatologist with experience starting over 1,000 dogs on Apoquel notes that many internet reports of "Apoquel caused my dog's cancer" likely represent dogs whose skin signs were already caused by an internal disease, including cancer, that had not yet been diagnosed when oclacitinib was started.

The honest summary: the data do not show that oclacitinib causes cancer in dogs. The data do show that immune modulation can make an existing cancer progress faster, which is why the label says to avoid the drug in dogs with a known neoplasia history and to monitor for new masses.

Histiocytomas and viral papillomas

A practical nuance the label does not emphasize: histiocytomas (benign skin growths common in young dogs) appear more frequently in dogs on oclacitinib. They also appear more frequently in dogs with atopic dermatitis regardless of medication. Most resolve spontaneously. Stopping Apoquel may speed resolution, but evidence is anecdotal. Viral papillomas can also be more persistent. Any new mass should be evaluated by a veterinarian — do not assume it is "just a histiocytoma."

Twice-daily dosing: when it is appropriate and when it raises risk

The label dosing protocol is 0.4–0.6 mg/kg twice daily for up to 14 days, then once daily thereafter. But some veterinarians prescribe extended twice-daily dosing for dogs whose itch breaks through on once-daily dosing.

A 2025–2026 review in Today's Veterinary Practice (Patterson, Jan/Feb 2026) notes that prolonged extralabel twice-daily dosing can achieve acceptable efficacy in a majority of dogs, but the author emphasizes "the risks of extralabel dosing and the role of regularly scheduled physical examinations, CBCs, and chemistry profiles" for dogs on such regimens. The message: if your dog is on twice-daily Apoquel long-term, blood work monitoring is not optional.

Drug interactions that matter

• Cyclosporine (Atopica): The label has not been evaluated for long-term concurrent use. Short-term overlap (transitioning between drugs) appears safe, but chronic co-administration of two immunosuppressive agents increases infection and neoplasia risk in ways the label cannot quantify.
• Glucocorticoids (prednisone, prednisolone): Same caveat. Short courses for flare-ups appear manageable. Chronic concurrent use is off-label and should prompt a re-evaluation of the overall treatment strategy.
• NSAIDs, antihistamines, allergy immunotherapy, vaccines: The label states these have been safely used alongside oclacitinib. No additional monitoring is required beyond standard precautions.

Red flags: when to call your veterinarian immediately

Contact your veterinarian right away if your dog on Apoquel develops:

• A new lump or mass — do not wait for the next scheduled recheck.
• Signs of infection — fever, lethargy, loss of appetite, coughing, increased respiratory rate, or worsening skin/ear infections that do not respond to treatment.
• Persistent GI signs — vomiting or diarrhea lasting more than 24–48 hours.
• Unexplained bruising or bleeding — could indicate bone marrow suppression affecting platelets.
• Behavioral changes — unusual aggression, restlessness, or profound lethargy.

What to ask at every recheck

If your dog is on long-term Apoquel, these are productive questions to bring to recheck appointments:

1. "Can we review my dog's latest blood work trends?" — not just whether values are "in normal range," but whether they are drifting.
2. "Are there new masses I should be concerned about?" — ask your veterinarian to do a full-body skin check.
3. "Is the current dose still the right one, or can we try stepping down?" — many dogs can be managed on less than daily dosing, especially when paired with topical therapy, immunotherapy, or environmental management.
4. "Should we be considering alternatives like Cytopoint?" — if infection frequency is increasing or blood work shows a downward trend, it may be time to re-evaluate.
5. "How is my dog's overall itch control, and what else can we address?" — secondary infections, flea exposure, and food triggers can all undermine Apoquel's effectiveness, leading to dose escalation that might be avoidable.

Bottom line

Apoquel's benefit-risk profile for chronic allergic itch in dogs is favorable when it is used according to the label with appropriate monitoring. The dogs that run into problems are usually the ones where monitoring lapses — where a slowly dropping white count goes unnoticed, a new mass is assumed benign, or twice-daily dosing becomes permanent without blood work oversight. The safety conversation is not a reason to avoid the drug. It is a reason to use it deliberately.

Sources

• Zoetis. Apoquel (oclacitinib maleate) Prescribing Information. NADA 141-345. https://www.zoetisus.com/content/_assets/docs/vmips/package-inserts/apoquel-prescribing-information.pdf
• FDA. Untitled Letter to Zoetis re: Apoquel Promotional Materials. https://www.fda.gov/media/113909/download
• FDA. 2021 Animal Drug Safety-Related Labeling Changes — Apoquel (oclacitinib tablet). https://www.fda.gov/animal-veterinary/drug-labels/2021-animal-drug-safety-related-labeling-changes
• Nederveld SM, Krautmann MJ, Mitchell J, et al. Safety of the Selective JAK1 Inhibitor Oclacitinib in Dogs. J Vet Pharmacol Ther. 2025. https://pubmed.ncbi.nlm.nih.gov/40018984/
• Cosgrove SB, Wren JA, Cleaver DM, et al. Long-term compassionate use of oclacitinib in dogs with atopic and allergic skin disease. Vet Dermatol. 2015;26(3):171-185. https://pubmed.ncbi.nlm.nih.gov/25688708/
• European Medicines Agency. Apoquel Summary of Product Characteristics. https://ec.europa.eu/health/documents/community-register/2013/20130912126630/anx_126630_en.pdf
• VCA Animal Hospitals. Oclacitinib — Know Your Pet. https://vcahospitals.com/know-your-pet/oclacitinib
• UW Veterinary Care. Apoquel Client Information Sheet. https://uwveterinarycare.wisc.edu/wp-content/uploads/2018/04/Apoquel-2018.pdf
• Pet Dermatology Clinic. Apoquel Side Effects — A Veterinary Dermatologist's Experience. https://www.petdermatologyclinic.com/apoquel-information
• Patterson C. Updates on JAK Inhibitors for Veterinary Dermatology. Today's Veterinary Practice. Jan/Feb 2026. https://todaysveterinarypractice.com/wp-content/uploads/sites/4/2025/12/TVP-2026-0102_JAK-Inhibitors.pdf
• UK Veterinary Medicines Directorate. FOI2025/00057 — Apoquel Side Effects: Adverse Event Frequencies. https://www.gov.uk/government/publications/vmd-foieir-requests-november-2025/foi202500057-apoquel-side-effects